Affordable Access

Publisher Website

104 P - Predictive factors for response to neoadjuvant chemotherapy in operable breast cancer > 3 cm

Authors
Journal
European Journal of Cancer
0959-8049
Publisher
Elsevier
Publication Date
Volume
32
Identifiers
DOI: 10.1016/0959-8049(96)84862-3

Abstract

A single institution study investigated the effect on objective response of 3-4 cycles of q 21 HD-Epirubicin or FEC50 or q 14 (+G-CSF) HD-Epirubicin or FEC or MMM, according the following factors: ER (+/-), PgR (+/-), Ki-67 L.I. (+/-), SBR grading (G2/G3) and menopausal status (pre/poat), in 53 pts. mean age 47 years (32–71), 26 premenopausal, 36T 2>3cm, 17T 3, 25 ER +, 21 PgR +, 14 Ki-67 L.I. +, 38 G 2, 15 G 3. Clinical results: in T 2 group CR was achieved in 13.8%, PR>50% in 55.4% and PR < 50% in 30.6%; in T 3 group there was no CR, 70.1% PR > 50%. and 29.9% PR < 50%. Univariate and multivariate analises were performed to evaluate the real relative influence of each prognostic factor in response. Significance of associations was tested bv the chi-square test. Univariate: Linear regression = independent variables vs response Ki-67 L.I. Menopause PgR G ER t 1.69 2.58 2.25 -92 -1.85 p 0.028 0.061 0.069 0.096 n.s. Linear discriminant function Ki-67 L.I. Menopause PgR G p 0.0665 0.0738 0.1071 0.1471 Our data demonstrate that four out of five considered variables have been proved useful in predicting the right place of each patient in the responder (Ki-67) L.I. +, Premenopause, PgR −, G 3) or non responder group (Ki-67 L.I. −, Postrmenopause, PgR +, G 2) in 42 out of 53 (79.24%) patients. These groups are determined by the value defined in the following equation: Response = 1.648 (costant) +PgR (1.010) - Ki-67 L.I. (1.277) -G(0.974) + Menopause (1.085) with a predictive power of -0.351 for the responder group (CR + PR>50%) and 0.812 for the non responder.

There are no comments yet on this publication. Be the first to share your thoughts.